Taysha Q2 Loss Widens on Surging R&D; Pivotal TSHA-102 Data Show 100% Response Rate, BLA Filing on Track for H1 2027
TSHA has more than doubled off its 52-week low of $2.685.
Summary
Taysha reported a wider Q2 net loss of $46.6 million as R&D costs surged for its pivotal TSHA-102 program, but clinical data showed a 100% response rate in the Phase 1/2 trial, keeping the BLA submission on track for H1 2027.
Key Events · Earnings and Guidance · TSHA
-
Q2 Net Loss Widens to $46.6M
Net loss increased to $46.6 million from $26.9 million in Q2 2025, driven by a near-doubling of R&D expenses to $38.6 million as the company advances BLA-enabling manufacturing and clinical trials.
-
100% Response Rate in REVEAL Part A
All 12 patients in the Phase 1/2 trial gained at least one developmental milestone post-TSHA-102, with a 100% response rate at 12 months — well above the FDA's 33% threshold for the pivotal trial.
-
Pivotal Trial Dosing Complete; BLA Filing in H1 2027
Dosing is complete in the 17-patient REVEAL pivotal trial and the 4-patient ASPIRE safety study. The company expects to submit a BLA in the first half of 2027 following a 6-month interim analysis.
-
Cash Runway into H2 2028
Cash and equivalents stood at $455.4 million as of June 30, 2026, providing a runway into the second half of 2028, though the accelerating burn rate suggests additional financing will be needed before commercialization.
Analysis · TSHA · Life Sciences
Taysha's Q2 results underscore the escalating cost of its pivotal-stage gene therapy program, with R&D spend nearly doubling year-over-year as the company races toward a BLA submission for TSHA-102 in Rett syndrome. The clinical update is the real driver: all 12 patients in the Phase 1/2 trial gained at least one developmental milestone, and the 100% response rate at 12 months handily beats the FDA's 33% threshold. With dosing complete in the pivotal and safety trials, the company is on a clear path to a BLA filing in the first half of 2027. The $455 million cash position funds operations into the second half of 2028, but the burn rate is accelerating — a reminder that another capital raise is likely before commercialization.
At the time of this filing, TSHA was trading at $6.34 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.1B. The 52-week trading range was $2.69 to $7.30. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.